Combining Fluorescent In Situ Hybridization (iFISH) data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group (IMWG) collaborative project

This study seeks to “assess the independent contributions of International Staging System (ISS) stage and cytogenetic abnormalities in predicting outcomes. This international effort used the International Myeloma Working Group database of 12,137 patients treated worldwide for myeloma at diagnosis, of whom 2,309 had cytogenetic studies and 5,387 had analyses by fluorescent in situ hybridization (iFISH).” The study demonstrated that risk assessment in myeloma is improved by combining both

  • iFISH data and
  • ISS Staging.


H Avet-Loiseau, BGM Durie, M Cavo, M Attal, N Gutierrez, J Haessler, H Goldschmidt, R Hajek, JH Lee, O Sezer, B Barlogie, J Crowley, R Fonseca, N Testoni, F Ross, SV Rajkumar, P Sonneveld, J Lahuerta, P Moreau and G Morgan on behalf of the International Myeloma Working Group

Click here to view article:

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.